Blended Polymer Reduces Catheter-Related Thrombus

Novel peripherally inserted central catheters (PICCs) have been designed to reduce the accumulation of catheter-related thrombus on and in the catheter.

The AngioDynamics BioFlo PICC is intended for use for an extended period of time for chemotherapy, antibiotic delivery, and other intravascular therapies. It does not contain antibiotics or antimicrobials, agents potentially associated with bacterial resistance. Instead, it is provided with Endexo technology, a permanent and noneluting integral polymer that is blended into the catheter shaft, and thus present throughout the catheter. The resultant passivating surface reduces platelet adhesion, protein adsorption, and thrombus formation. And since it is not superficial or transient (such as in coatings or impregnated materials), Endexo provides long-term durability.


The AngioDynamics BioFlo PICC is also equipped with Pressure Activated Safety Valve (PASV) technology, designed to automatically resist backflow and reduce blood reflux on the inside of the catheter. The valve automatically closes after infusion or upon disconnection, and remains closed during commonly experienced increases in central venous pressure (CVP). In vitro blood loop-model tests have shown that the BioFlo PICC has 87% less thrombus accumulation on its surface compared to commonly used PICCs, based on platelet count. The AngioDynamics BioFlo PICC is a product of AngioDynamics (Latham, NY, USA), and has been approved by the US Food and Drug Administration (FDA).

“BioFlo technology shows promise in decreasing the accumulation of catheter-related thrombus without incorporation of heparin, antibiotics, antimicrobials or any other transient materials typically associated with coated or impregnated technologies,” said Joseph DeVivo, president and CEO of AngioDynamics. “BioFlo technology provides AngioDynamics with a truly disruptive technology which we believe will drive increased demand for our vascular access products.”

As an additive, Endexo has significant manufacturing advantages over other antithrombogenic coating or impregnation alternatives, and does not change the mechanical design parameters or functional properties of the underlying medical device. By enhancing the biocompatibility of medical devices, Endexo may ultimately improve their safety and effectiveness and advance the quality of care provided to patients.

Related Links:
AngioDynamics